SURFACE LOGIX BEGINS TRIAL FOR GASTROINTESTINAL-SPECIFIC MTP INHIBITOR

Surface Logix today announced the commencement of a Phase I clinical trial for SLx-4090, a novel, Microsomal Triglyceride Transfer Protein (MTP) inhibitor targeting dyslipidemia.

The trial is a single-center, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of a range of single orally administered doses of SLx-4090 in healthy male subjects.